# US 2013/0156702 A1 · Methods for the treatment and the diagnosis of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156702 A1
- Document ID: US20130156702A1
- Status: Published application
- Kind: A1
- Application number: 13/819,911
- Filed: 2010-09-02
- Published: 2013-06-20
- Earliest claimed: 2010-09-02
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Inventors: Gérard Friedlander; Laurent Beck; Christine Salaün; Christine Leroy
- Web page: https://patentgrep.com/patent/US20130156702A1

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 49/00: Preparations for testing in vivo
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver cancer such as hepatocellular carcinoma (HCC).

## Claims

### Claim 1

A method for detecting or diagnosing a cancer and/or metastases in a patient comprising the step of determining an expression level of the phosphate transporter PiT1 gene in a biological sample obtained from said patient.

### Claim 2

A method for staging a cancer in a patient having cancer comprising the step of determining an expression level of the PiT1 gene in a biological sample obtained from said patient.

### Claim 3

A method for screening an asymptomatic patient at risk for cancer, said method comprising the step of determining an expression level of the PiT1 gene in a biological sample obtained from said patient.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said expression level of the PiT1 gene is determined by measuring a quantity of PiT1 mRNA, and wherein and said biological sample is a tissue sample.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said tissue sample is a tumor sample.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said cancer is a liver cancer.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the liver cancer is a hepatocellular carcinoma (HCC).

### Claim 8

A method of detecting and localizing cancer cells and/or metastases stemming from cancer cells in the body of a patient, comprising the steps of
administering to said patient a labeled agent which binds to PiT1 in a quantity sufficient for imaging said patient,
subjecting said body to imaging to produce images, and
using said images to detect and localize said cancer cells and/or said metastases.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the cancer cells are liver cancer cells.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said method is a method of detecting and localizing hepatic carcinoma nodules in situ in the body of a patient.

### Claim 11

A kit for detecting or diagnosing a cancer and/or metastases in a patient, wherein said kit comprises means for determining the expression level of a PiT1 gene in a biological sample obtained from said patient.

### Claim 12

A kit for detecting and localizing cancer cells and/or metastases stemming from cancer cells in the body of a patient, wherein said kit comprises a labelled agent which binds to PiT1.

### Claim 13 (depends on 12)

The kit according to claim 12, wherein said agent is an anti-PiT1 antibody, an aptamer or a polypeptide corresponding to the envelope proteins of GALV (Gibbon Ape Leukemia Virus), or derivatives thereof.

### Claim 14

A method for preventing or treating a cancer in a patient, comprising the step of administrating an effective amount of an inhibitor of the activation of PiT1 to a subject in need thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the inhibitor of the activation of the PiT1 is an agent down-regulating the expression of PiT1.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the agent down-regulating the expression of PiT1 is a small inhibitory RNA (siRNA).

### Claim 17 (depends on 14)

The method according to claim 14, wherein the cancer is a liver cancer.

### Claim 18

A method for preventing or treating a cancer in a patient, comprising the step of administering to said patient an effective amount of PiT1-specific binding molecule conjugated to a chemotherapeutic agent.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said PiT1-specific binding molecule is an anti-PiT1 antibody or an anti-PiT1 aptamer.

### Claim 20 (depends on 18)

The method according to claim 18, wherein said PiT1-specific binding molecule is a polypeptide corresponding to the envelope proteins of GALV (Gibbon Ape Leukemia Virus), or derivatives thereof.

### Claim 21 (depends on 18)

The method according to claim 18, wherein the cancer is a liver cancer.

### Claim 22

A pharmaceutical composition comprising an inhibitor of the activation of PiT1 or a PiT1-specific binding molecule conjugated to a chemotherapeutic agent.

### Claim 23

A method for screening a drug for the prevention or the treatment of cancer comprising the steps consisting of:
a) providing a plurality of cells expressing PiT1 on their surface;
b) incubating said cells with a candidate compound;
c) determining whether said candidate compound binds to and inhibits PiT1; and
d) selecting the candidate compound that binds to and inhibits PiT1, and optionally
e) administering the candidate compound selected at step d) to an animal model of cancer to validate the therapeutic and/or protective effects of said candidate compound.

### Claim 24 (depends on 23)

The method of claim 23, wherein said animal model is an animal model of liver cancer.
